Last reviewed · How we verify
NCT05744700
Safety and Tolerability Trial of Microbial Inulinase
NA trial testing Inulinase in Digestive Health in 60 participants. Completed in 6 October 2023.
6 October 2023
Quick facts
| Lead sponsor | BIO-CAT, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 60 |
| Start date | 28 April 2023 |
| Primary completion | 6 October 2023 |
| Estimated completion | 6 October 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Inulinase
- Maltodextrin placebo
Conditions studied
- Digestive Health — all drugs for Digestive Health →
- Gastrointestinal Health — all drugs for Gastrointestinal Health →
Sponsor
BIO-CAT, Inc.
Who can join
Adults 20 to 60, any sex, with Digestive Health or Gastrointestinal Health. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objectives of this clinical trial are to: 1) assess the effect of microbial inulinase on gastrointestinal symptoms in healthy participants compared to a placebo, and 2) to assess the safety and tolerability of microbial inulinase in healthy participants compared to a placebo.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Safety and Tolerability of Microbial Inulinase Supplementation in Healthy Adults: A Randomized, Placebo-Controlled Trial.
Garvey SM, LeMoire A, Wang J, Lin L, et al · · 2024 · cited 1× · PMID 39318719 · DOI 10.1016/j.gastha.2024.05.013
Verify or expand the search:
- PubMed search for NCT05744700
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Digestive Health
Currently open trials in the same condition.
- NCT07421596 — An 8-Week Study Evaluating Gut and Digestive Health After Use of a Dietary Supplement System · NA · recruiting
- NCT07271316 — Alii Supplement Study · Phase 2 · recruiting
- NCT06946017 — Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints · NA · recruiting
Other BIO-CAT, Inc. trials
Trials by the same sponsor.
- NCT06628869 — The Effects of Oral Fructanase Administration on Gastrointestinal Symptoms After Inulin Challenge in Healthy Adults · NA · completed
- NCT05957185 — Effects of Microbial Protease Supplementation on Postprandial Plasma Amino Acid Concentrations and Appetite · NA · completed
- NCT05295134 — Effect of Candida Rugosa Lipase on Serum Triglyceride Lowering · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05744700 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BIO-CAT, Inc.
- Last refreshed: 27 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05744700.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing